MedTrace Logo

A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer

NCT04951154 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2025-08-19

No results posted yet for this study

Summary

The purpose of this study is to assess spontaneous residual viable tumor cells (RVT) in the surgically resected tumor (Non-small cell lung cancer \[NSCLC\]).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

OTHER

Bronchoscopic Biopsy

Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.

OTHER

Blood Sample

Blood samples will be obtained to measure circulating biomarkers.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2023-05-15
Completion
2023-05-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04951154 on ClinicalTrials.gov